Reported 3 months ago
Vaxcyte, Inc. (NASDAQ:PCVX) experienced a significant drop in stock value during Q1 2025, reflecting a broader decline in small-cap stocks. The company, focused on developing vaccines, faced challenges with its VAX-24 trial results and the resignation of a key FDA leader, leading to investor concerns. Despite these issues, Vaxcyte is optimistic about its future trials.
Source: YAHOO